{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:26:22Z","timestamp":1787012782396,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472795"],"award-info":[{"award-number":["82472795"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200090"],"award-info":[{"award-number":["82200090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62273099"],"award-info":[{"award-number":["62273099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["24ZR1411000"],"award-info":[{"award-number":["24ZR1411000"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J08348"],"award-info":[{"award-number":["2024J08348"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J05297"],"award-info":[{"award-number":["2023J05297"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Program of Shanghai Municipal Health Commission","award":["20244Y0100"],"award-info":[{"award-number":["20244Y0100"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22Y11905300"],"award-info":[{"award-number":["22Y11905300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["ZSLCYJ202338"],"award-info":[{"award-number":["ZSLCYJ202338"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01224-3","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:24:18Z","timestamp":1779427458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TFPI2 expression predicts resistance to immunotherapy plus tyrosine kinase inhibitor and informs first-line therapy selection in metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Jiajun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1224_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram, A. Jemal, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024)","journal-title":"CA Cancer J. Clin."},{"key":"1224_CR2","first-page":"529","volume":"82","author":"L Bukavina","year":"2022","unstructured":"L. Bukavina, K. Bensalah, F. Bray, M. Carlo, B. Challacombe, J.A. Karam, W. Kassouf, T. Mitchell, R. Montironi, T. O\u2019Brien, V. Panebianco, G. Scelo, B. Shuch, H. van Poppel, C.D. Blosser, S.P. Psutka, Epidemiol. Ren. Cell. Carcinoma: 2022 Update Eur. Urol. 82, 529\u2013542 (2022)","journal-title":"Epidemiol. Ren. Cell. Carcinoma: 2022 Update Eur. Urol."},{"key":"1224_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"R.L. Siegel, T.B. Kratzer, A.N. Giaquinto, H. Sung, A. Jemal, Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025)","journal-title":"CA Cancer J. Clin."},{"key":"1224_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"B. Ljungberg, L. Albiges, Y. Abu-Ghanem, J. Bedke, U. Capitanio, S. Dabestani, S. Fern\u00e1ndez-Pello, R.H. Giles, F. Hofmann, M. Hora, T. Klatte, T. Kuusk, T.B. Lam, L. Marconi, T. Powles, R. Tahbaz, A. Volpe, A. Bex, European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur. Urol. 82, 399\u2013410 (2022)","journal-title":"Eur. Urol."},{"key":"1224_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"B.I. Rini, E.R. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Souli\u00e8res, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S.J. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R.S. McDermott, J. Bedke, S. Tartas, Y. Chang, S. Tamada, Q. Shou, R.F. Perini, M. Chen, M.B. Atkins, T. Powles, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl. J. Med. 380, 1116\u20131127 (2019)","journal-title":"N Engl. J. Med."},{"key":"1224_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"R. Motzer, B. Alekseev, S. Rha, C. Porta, M. Eto, T. Powles, V. Gr\u00fcnwald, T.E. Hutson, E. Kopyltsov, M.J. M\u00e9ndez-Vidal, V. Kozlov, A. Alyasova, S. Hong, A. Kapoor, T. Alonso Gordoa, J.R. Merchan, E. Winquist, P. Maroto, J.C. Goh, M. Kim, H. Gurney, V. Patel, A. Peer, G. Procopio, T. Takagi, B. Melichar, F. Rolland, U. De Giorgi, S. Wong, J. Bedke, M. Schmidinger, C.E. Dutcus, A.D. Smith, L. Dutta, K. Mody, R.F. Perini, D. Xing, Choueiri, Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl. J. Med. 384, 1289\u20131300 (2021)","journal-title":"N Engl. J. Med."},{"key":"1224_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"R.J. Motzer, K. Penkov, J. Haanen, B. Rini, L. Albiges, M.T. Campbell, B. Venugopal, C. Kollmannsberger, S. Negrier, M. Uemura, J.L. Lee, A. Vasiliev, W.H.J. Miller, H. Gurney, M. Schmidinger, J. Larkin, M.B. Atkins, J. Bedke, B. Alekseev, J. Wang, M. Mariani, P.B. Robbins, A. Chudnovsky, C. Fowst, S. Hariharan, B. Huang, A. di Pietro, T.K. Choueiri, Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl. J. Med. 380, 1103\u20131115 (2019)","journal-title":"N Engl. J. Med."},{"key":"1224_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"T.K. Choueiri, T. Powles, M. Burotto, B. Escudier, M.T. Bourlon, B. Zurawski, V.M. Oyervides Ju\u00e1rez, J.J. Hsieh, U. Basso, A.Y. Shah, C. Su\u00e1rez, A. Hamzaj, J.C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J.P. Feregrino, J. \u017bo\u0142nierek, D. Pook, E.R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M.A. Maurer, B. Simsek, F. Ejzykowicz, G.M. Schwab, A.B. Apolo, R.J. Motzer, Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl. J. Med. 384, 829\u2013841 (2021)","journal-title":"N Engl. J. Med."},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/oxfordjournals.jbchem.a124648","volume":"116","author":"Y Miyagi","year":"1994","unstructured":"Y. Miyagi, N. Koshikawa, H. Yasumitsu, E. Miyagi, F. Hirahara, I. Aoki, K. Misugi, M. Umeda, K. Miyazaki, cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J. Biochem. 116, 939\u2013942 (1994)","journal-title":"J. Biochem."},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1055\/s-2007-991532","volume":"33","author":"E Sierko","year":"2007","unstructured":"E. Sierko, M.Z. Wojtukiewicz, W. Kisiel, The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb. Hemost. 33, 653\u2013659 (2007)","journal-title":"Semin Thromb. Hemost."},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cancergencyto.2009.11.004","volume":"197","author":"H Takada","year":"2010","unstructured":"H. Takada, N. Wakabayashi, O. Dohi, K. Yasui, C. Sakakura, S. Mitsufuji, M. Taniwaki, T. Yoshikawa, Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet. Cytogenet. 197, 16\u201324 (2010)","journal-title":"Cancer Genet. Cytogenet."},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12967-014-0237-7","volume":"12","author":"Y Lai","year":"2014","unstructured":"Y. Lai, R. He, J. Chou, M.W. Chan, Y. Li, C. Tai, Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma. J. Transl Med. 12, 237 (2014)","journal-title":"J. Transl Med."},{"key":"1224_CR13","doi-asserted-by":"publisher","first-page":"84054","DOI":"10.18632\/oncotarget.21097","volume":"8","author":"H Hu","year":"2017","unstructured":"H. Hu, X. Chen, C. Wang, Y. Jiang, J. Li, X. Ying, Y. Yang, B. Li, C. Zhou, J. Zhong, D. Wu, J. Ying, S. Duan, The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget. 8, 84054\u201384065 (2017)","journal-title":"Oncotarget"},{"key":"1224_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s10555-024-10205-7","volume":"43","author":"MZ Wojtukiewicz","year":"2024","unstructured":"M.Z. Wojtukiewicz, M. Mysliwiec, A. Tokajuk, J. Kruszewska, B. Politynska, A. Jamroze, A.M. Wojtukiewicz, D.G. Tang, K.V. Honn, Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis. Cancer Metastasis Rev. 43, 1185\u20131204 (2024)","journal-title":"Cancer Metastasis Rev."},{"key":"1224_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/ijtm4030028","volume":"4","author":"H Kobayashi","year":"2024","unstructured":"H. Kobayashi, S. Imanaka, S. Matsubara, H. Shigetomi, C. Yoshimoto, Dual Role of Tissue Factor Pathway Inhibitor 2\u2014A Novel Serodiagnostic Marker for Ovarian Cancer\u2014In Human Cancers. Int. J. Translational Med. 4, 419\u2013438 (2024)","journal-title":"Int. J. Translational Med."},{"key":"1224_CR16","doi-asserted-by":"publisher","first-page":"28639","DOI":"10.1038\/s41598-024-80248-x","volume":"14","author":"H Ito","year":"2024","unstructured":"H. Ito, R. Jikuya, S. Myoba, T. Tatenuma, G. Noguchi, D. Ueno, Y. Ito, M. Komeya, K. Muraoka, M. Yao, H. Hasumi, N. Nakaigawa, K. Makiyama, Tissue factor pathway inhibitor 2 (TFPI2) is a potential serum biomarker for clear cell renal carcinoma. Sci. Rep. 14, 28639 (2024)","journal-title":"Sci. Rep."},{"key":"1224_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009)","journal-title":"Eur. J. Cancer"},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"R.J. Motzer, P.B. Robbins, T. Powles, L. Albiges, J.B. Haanen, J. Larkin, X.J. Mu, K.A. Ching, M. Uemura, S.K. Pal, B. Alekseev, G. Gravis, M.T. Campbell, K. Penkov, J.L. Lee, S. Hariharan, X. Wang, W. Zhang, J. Wang, A. Chudnovsky, A. di Pietro, A.C. Donahue, T.K. Choueiri, Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733\u20131741 (2020)","journal-title":"Nat. Med."},{"key":"1224_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"M.J. Goldman, B. Craft, M. Hastie, K. Repe\u010dka, F. McDade, A. Kamath, A. Banerjee, Y. Luo, D. Rogers, A.N. Brooks, J. Zhu, D. Haussler, Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020)","journal-title":"Nat. Biotechnol."},{"key":"1224_CR20","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1245\/s10434-016-5173-8","volume":"23","author":"SK Swisher","year":"2016","unstructured":"S.K. Swisher, Y. Wu, C.A. Castaneda, G.R. Lyons, F. Yang, C. Tapia, X. Wang, S.A.A. Casavilca, R. Bassett, M. Castillo, A. Sahin, E.A. Mittendorf, Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann. Surg. Oncol. 23, 2242\u20132248 (2016)","journal-title":"Ann. Surg. Oncol."},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"e1515611","DOI":"10.1080\/2162402X.2018.1515611","volume":"8","author":"J Wang","year":"2019","unstructured":"J. Wang, L. Liu, Q. Bai, C. Ou, Y. Xiong, Y. Qu, Z. Wang, Y. Xia, J. Guo, J. Xu, Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. OncoImmunology. 8, e1515611 (2019)","journal-title":"OncoImmunology"},{"key":"1224_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.32948\/auo.2023.12.30","volume":"41","author":"J Wang","year":"2023","unstructured":"J. Wang, S. Zhang, Y. Wang, Y. Zhu, X. Xu, J. Guo, Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. Urol. Oncol. 41, 13\u201351 (2023)","journal-title":"Urol. Oncol."},{"key":"1224_CR23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","volume":"23","author":"Y Vano","year":"2022","unstructured":"Y. Vano, R. Elaidi, M. Bennamoun, C. Chevreau, D. Borchiellini, D. Pannier, D. Maillet, M. Gross-Goupil, C. Tournigand, B. Laguerre, P. Barth\u00e9l\u00e9my, E. Coquan, G. Gravis, N. Houede, M. Cancel, O. Huillard, P. Beuzeboc, L. Fournier, A. M\u00e9jean, X. Cathelineau, N. Doumerc, P. Paparel, J. Bernhard, A. de la Taille, K. Bensalah, T. Tricard, T. Waeckel, G. Pignot, E. Braychenko, S. Caruso, C. Sun, V. Verkarre, G. Lacroix, M. Moreira, M. Meylan, A. Bougou\u00efn, L. Phan, C. Thibault-Carpentier, J. Zucman-Rossi, W.H. Fridman, C. Saut\u00e8s-Fridman, S. Oudard, Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 23, 612\u2013624 (2022)","journal-title":"Lancet Oncol."},{"key":"1224_CR24","doi-asserted-by":"publisher","first-page":"1080403","DOI":"10.3389\/fimmu.2022.1080403","volume":"13","author":"T Wang","year":"2022","unstructured":"T. Wang, W. Jian, W. Xue, Y. Meng, Z. Xia, Q. Li, S. Xu, Y. Dong, A. Mao, C. Zhang, Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments. Front. Immunol. 13, 1080403 (2022)","journal-title":"Front. Immunol."},{"key":"1224_CR25","doi-asserted-by":"publisher","first-page":"1210910","DOI":"10.3389\/fonc.2023.1210910","volume":"13","author":"H Wang","year":"2023","unstructured":"H. Wang, Z. Liu, Y. Du, X. Cheng, S. Gao, Y. Gao, P. Shang, TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma. Front. Oncol. 13, 1210910 (2023)","journal-title":"Front. Oncol."},{"key":"1224_CR26","doi-asserted-by":"publisher","first-page":"1207551","DOI":"10.3389\/fonc.2023.1207551","volume":"13","author":"X Sun","year":"2023","unstructured":"X. Sun, Z. Liu, Q. Yu, Y. Chen, Y. Sun, Q. Zhu, J. Yang, R. Jiang, PLAC8 is an innovative biomarker for immunotherapy participating in remodeling the immune microenvironment of renal clear cell carcinoma. Front. Oncol. 13, 1207551 (2023)","journal-title":"Front. Oncol."},{"key":"1224_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"A. Kallies, D. Zehn, D.T. Utzschneider, Precursor exhausted T cells: key to successful immunotherapy? Nat. Rev. Immunol. 20, 128\u2013136 (2020)","journal-title":"Nat. Rev. Immunol."},{"key":"1224_CR28","first-page":"18","volume":"21","author":"C Kim","year":"2020","unstructured":"C. Kim, J. Jin, C.M. Weyand, J.J. Goronzy, The transcription factor TCF1 in T cell differentiation and aging. Int. J. Mol. Sci. 21, 18 (2020)","journal-title":"Int. J. Mol. Sci."},{"key":"1224_CR29","doi-asserted-by":"publisher","first-page":"1709852","DOI":"10.3389\/fimmu.2025.1709852","volume":"16","author":"X Guo","year":"2025","unstructured":"X. Guo, S. Ma, J. Wang, Y. Fu, W. Ma, Terminally exhausted CD8(+) T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. Front. Immunol. 16, 1709852 (2025)","journal-title":"Front. Immunol."},{"key":"1224_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","volume":"25","author":"D Hanahan","year":"2025","unstructured":"D. Hanahan, O. Michielin, M.J. Pittet, Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat. Rev. Cancer. 25, 41\u201358 (2025)","journal-title":"Nat. Rev. Cancer"},{"key":"1224_CR31","doi-asserted-by":"crossref","unstructured":"H. Kobayashi, H. Shigetomi, S. Imanaka, reassessing the role of tissue factor pathway inhibitor 2 in neoplastic and non-neoplastic lesions. Cancers (basel). 17 (2025)","DOI":"10.3390\/cancers17091447"},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41590-023-01605-y","volume":"24","author":"L Pang","year":"2023","unstructured":"L. Pang, M. Dunterman, S. Guo, F. Khan, Y. Liu, E. Taefi, A. Bahrami, C. Geula, W. Hsu, C. Horbinski, C.D. James, P. Chen, Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma. Nat. Immunol. 24, 1654\u20131670 (2023)","journal-title":"Nat. Immunol."},{"key":"1224_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12950-023-00357-8","volume":"20","author":"M Guo","year":"2023","unstructured":"M. Guo, Z. Xia, Y. Hong, H. Ji, F. Li, W. Liu, S. Li, H. Xin, K. Tan, Z. Lian, The TFPI2-PPAR\u03b3 axis induces M2 polarization and inhibits fibroblast activation to promote recovery from post-myocardial infarction in diabetic mice. J. Inflamm. (Lond). 20, 35 (2023)","journal-title":"J. Inflamm. (Lond)"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01224-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:55:50Z","timestamp":1787010950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01224-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01224-3","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study followed the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of Zhongshan Hospital, Fudan University (B2021-119). Informed consent was obtained from each participant.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"111"}}